Syndax Pharmaceuticals Inc SNDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $22.71
- Day Range
- $22.24–23.45
- 52-Week Range
- $9.27–25.59
- Bid/Ask
- $22.12 / $22.70
- Shares Outstanding
- 88.61M
- Market Cap
- $2.02B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.14
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 298
- Website
- https://www.syndax.com
Valuation
|
Metric
|
SNDX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 48.50 |
Price/Sales | 9.14 |
Price/Cash Flow | — |
Price/Earnings
SNDX
Financial Strength
|
Metric
|
SNDX
|
|---|---|
Quick Ratio | 4.90 |
Current Ratio | 5.47 |
Interest Coverage | −5.98 |
Quick Ratio
SNDX
Profitability
|
Metric
|
SNDX
|
|---|---|
Return on Assets (Normalized) | −34.77% |
Return on Equity (Normalized) | −163.31% |
Return on Invested Capital (Normalized) | −68.06% |
Return on Assets
SNDX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|vj<G<> | LOCK|L@lp | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|G%$Kr?? | LOCK|N$vl | $71B | |||
| argenx SE ADR
ARGX
| LOCK|?mxYh$ | LOCK|w% | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?Y&&fnD | LOCK|X@ | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|R&MH%>N | LOCK|SLV>^ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$l&G!Jl& | LOCK|gjz<n | $26B | |||
| Moderna Inc
MRNA
| LOCK|zVhjZvr | LOCK|?^ | $25B | |||
| Incyte Corp
INCY
| LOCK|gNqw%>Q | LOCK|NW | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|<^!l>@ | LOCK|hD^ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|BW%hS#< | LOCK|^x& | $16B |
United States